To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activites in Patients With Chronic Lung Disease With Obstruction of Airways

2014/3/7 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: placebo to tiotropium + olodaterol; Drug: tiotropium; Drug: olodaterol; Drug: tiotropium
Sponsor: Boehringer Ingelheim
Not yet recruiting - verified March 2014

Steroids In Eosinophil Negative Asthma

2014/2/10 12:00

Condition: Asthma
Interventions: Drug: Asmanex 220 mcg; Drug: Respimat 2.5 mcg; Drug: Placebo
Sponsors: Milton S. Hershey Medical Center; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2014

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

2014/2/7 12:00

Conditions: Pulmonary Disease, Chronic Obstructive; Asthma
Interventions: Drug: LAS190792 Dose 1; Drug: LAS190792 Dose 2; Drug: LAS190792 Dose 3; Drug: LAS190792 Dose 4; Drug: LAS190792 Dose 5; Drug: LAS190792 Dose 6; Drug: LAS190792 Dose 1 (Part 2); Drug: LAS190792 Dose 2 (Part 2); Drug: Tiotropium 18 μg; Drug: Indacaterol 150 μg; Drug: Placebo
Sponsor: Almirall, S.A.
Recruiting - verified February 2014

Evaluation of Long-Acting Muscarinic Antagonists in COPD

2014/1/15 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Aclidinium
Sponsors: University of Dundee; Almirall Limited
Not yet recruiting - verified January 2014

Ultra-long Acting Bronchodilator Therapy in Asthmatics

2014/1/15 12:00

Condition: Asthma
Interventions: Drug: Indacaterol; Drug: Indacaterol and tiotropium
Sponsors: University of Dundee; Tenovus Scotland
Not yet recruiting - verified January 2014

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

2014/1/7 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol; Drug: tiotropium; Drug: Placebo; Drug: tiotropium; Drug: olodaterol
Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified January 2014

Bronchoreversibility and Radiologic Morphology of Emphysema

2013/12/6 12:00

Conditions: Emphysema; COPD
Intervention: Drug: Bronchodilators
Sponsor: University of Rome Tor Vergata
Recruiting - verified December 2013

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticason Propionate + Salmeterol Fixed Dose Combination in COPD Patients

2013/10/22 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone propionate; Drug: salmeterol; Drug: placebo; Drug: fluticason propionate; Drug: placebo; Drug: tiotropium; Drug: olodaterol; Drug: olodaterol; Drug: placebo; Drug: placebo; Drug: tiotropium; Drug: salmeterol
Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified October 2013

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease

2013/10/14 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: placebo; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium; Drug: olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified October 2013

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

2013/10/8 12:00

Condition: COPD
Interventions: Drug: Glycopyrronium; Drug: Tiotropium; Drug: Placebo to glycopyrronium; Drug: Placebo to tiotropium
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified October 2013

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

2013/9/4 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium Bromide 2.5 µg; Drug: Indacterol 300 µg; Drug: Tiotropium Bromide 18 µg; Drug: Indacterol 150 µg
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified September 2013

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

2013/8/9 12:00

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: NVA237; Drug: Tiotropium; Drug: Placebo to NVA237; Drug: Placebo to tiotropium; Drug: Salbutamol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified August 2013

Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients

2013/7/31 12:00

Condition: COPD Exacerbation
Intervention:
Sponsors: AstraZeneca; AstraZeneca; HealthCore, Inc.
Not yet recruiting - verified August 2013

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

2013/7/26 12:00

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: BDP/FF/GB; Drug: Tiotropium; Drug: BDP/FF + Tiotropium
Sponsors: Chiesi Farmaceutici S.p.A.; Chiesi Farmaceutici S.p.A.
Not yet recruiting - verified July 2013

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 Mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium.

2013/7/11 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg; Drug: Tiotropium 18 mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified July 2013

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

2013/4/18 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: NVA237; Drug: Tiotropium Respimat®
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified July 2013

Preference Tiotropium Respimat Study in COPD

2013/3/12 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Device: Group1:Spiriva® Respimat®; Device: Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified July 2013

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

2013/2/4 12:00

Condition: COPD
Interventions: Drug: Tiotropium HFA BAI 4.5 mcg; Drug: Tiotropium HFA BAI 9.0 mcg; Drug: SPIRIVA® HandiHaler® 18 mcg/day; Drug: Spiriva® Respimat® 5 mcg/day
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Active, not recruiting - verified July 2013

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

2012/12/6 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone propionate/salmeterol 50/250mcg; Drug: fluticasone propionate/salmeterol placebo; Drug: tiotropium bromide 18mcg; Drug: tiotropium bromide placebo; Drug: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013

A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese

2012/10/8 12:00

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium (high dose) + Olodaterol; Drug: Tiotropium (low dose) + Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Completed - verified July 2013